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Abstract
Background: Arsenic trioxide has been demonstrated as an effective anti-cancer drug against leukemia and solid
tumors both in vitro and in vivo. However, recent phase II trials demonstrated that single agent arsenic trioxide was
poorly effective against hepatocellular carcinoma (HCC), which might be due to drug resistance.
Methods: Mutation detection of p53 gene in arsenic trioxide resistant HCC cell lines was performed. The therapeutic
effects of arsenic trioxide and Nutlin-3 on HCC were evaluated both in vitro and in vivo. A series of experiments
including MTT, apoptosis assays, co-Immunoprecipitation, siRNA transfection, lentiviral infection, cell migration,
invasion, and epithelial-mesenchy-mal transition (EMT) assays were performed to investigate the underlying
mechanisms.
Results: The acquisition of p53 mutation contributed to arsenic trioxide resistance and enhanced metastatic
potential of HCC cells. Mutant p53 (Mutp53) silence could re-sensitize HCC resistant cells to arsenic trioxide
and inhibit the metastatic activities, while mutp53 overexpression showed the opposite effects. Neither arsenic
trioxide nor Nutlin-3 could exhibit obvious effects against arsenic trioxide resistant HCC cells, while combination of
them showed significant effects. Nutlin-3 can not only increase the intracellular arsenicals through inhibition of p-gp
but also promote the p73 activation and mutp53 degradation mediated by arsenic trioxide. In vivo experiments
indicated that Nutlin-3 can potentiate the antitumor activities of arsenic trioxide in an orthotopic hepatic tumor model
and inhibit the metastasis to lung.
Conclusions: Acquisitions of p53 mutations contributed to the resistance of HCC to arsenic trioxide. Nutlin-3 could
overcome arsenic trioxide resistance and inhibit tumor metastasis through p73 activation and promoting mutant p53
degradation mediated by arsenic trioxide.
Keywords: Arsenic trioxide resistance, Nutlin-3, Metastasis, p53 mutation, p73, Hepatocellular carcinoma
Background
Arsenic trioxide is a documented environmental toxicant
and a potent chemotherapeutic agent, which has been used
therapeutically for decades [1]. Besides being an anticancer
drug against acute promyelocytic leukemia (APL), arsenic
trioxide has also been proved as an effective compound
that can inhibit the growth of many solid tumors both
in vitro and in vivo [1,2]. It has been reported that liver is
the most important site of arsenic biotransformation by al-
ternating reduction of pentavalent arsenic to trivalent and
addition of a methyl group from S-adenosylmethionine [3].
This evidence suggests that the hepatocellular carcinoma
(HCC) cells could be more likely to be killed as a result of
the aggregation of intracellular arsenicals after arsenic tri-
oxide treatment. However, a recent phase II trial showed
that single agent arsenic trioxide was poorly effective
against advanced liver cancer with failure to increase the
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http://www.molecular-cancer.com/content/13/1/133five-year survival rates [4], which was inconsistent with the
in vitro reports. Although lots of factors could explain the
inefficacy of arsenic trioxide in liver cancer patients, anti-
cancer drug resistance might be the most important reason
for this problem [5].
The increased drug efflux is defined as a characteristic
of the multidrug resistant phenotype. Overexpression of
transporters from ATP-binding cassette (ABC) super-
family is one of the most common reasons contributed
to drug resistance. It was reported that the As-GSH con-
jugates is substrates of some ABC transporter proteins
and could be pumped out by the ABC superfamily mem-
bers [6,7]. In our previous study, we found that arsenic
trioxide resistant HCC cells overexpressed p-glycoprotein
(p-gp), which could decrease the intra-cellular arsenicals
[5]. The resistant cells also overexpressed MDM2, which
could inactivate p53 or p73, leading to the defence of
apoptosis induced by arsenic trioxide. Interestingly, the
expression of p53 was increased in arsenic trioxide resist-
ant cells, suggesting there might be p53 mutations, which
could lead to the stabilization of p53. In the current
study, we hypothesized that long-term exposure of cells
to arsenic trioxide in the stepwise selection of arsenic
trioxide resistant HCC cells induced p53 mutations,
which can result in arsenic trioxide resistance. Fortunately,
unlike p53, another member of the p53 family, p73, is
rarely mutated in cancers [8]. In addition, a few stimuli,
including arsenic trioxide, have been identified to induce
p73 and subsequent apoptosis in cancer cells [8,9]. How-
ever, although arsenic trioxide could induce p73, some
negative moderators of p73, such as mutant p53 (mutp53)
and MDM2 can suppress the apoptotic function of p73
[10]. As reported, the most common p53 mutation is
single amino acid substitutions in the DNA binding do-
main of the p53 protein. In addition to the loss of tumor
suppressive activities of wild-type p53, many tumor-
associated mutp53 proteins gain new oncogenic func-
tions, defined as gain-of-function (GOF), which enable
them to promote tumorigenesis, metastasis and chemore-
sistance [11,12]. Therefore, we hypothesized that p53
mutation could be an ideal target to restore the sensi-
tivity of HCC resistant cells to arsenic trioxide and in-
hibit HCC tumor metastasis.
Nutlin-3, a novel MDM2 inhibitor, has been shown to
inhibit the p53-MDM2 or p73-MDM2 interaction, lead-
ing to the stabilization of p53 or p73 protein [10,13].
Furthermore, Nutlin-3 has also been reported to inter-
fere with p-gp-mediated drug efflux for acting as a trans-
porter substrate [14]. It revealed a potential therapeutic
way for HCC resistant cells, especially in combination
with arsenic trioxide. We designed this study to investi-
gate the underlying mechanism of arsenic trioxide resist-
ance and to evaluate whether Nutlin-3 could reverse the
resistance.
Results
Effects of arsenic trioxide and Nutlin-3 on parental and
arsenic trioxide resistant HCC cell lines
The sensitivity of HepG2, SMMC7721, HuH-7, Hep3B,
HepG2/As and SMMC7721/As cells to arsenic trioxide
or Nutlin-3 was examined by MTT assay after incuba-
tion with arsenic trioxide (48 h) or Nutlin-3 (72 h) re-
spectively (Figure 1A,B). The IC50 of arsenic trioxide in
HepG2/As or SMMC7721/As cells was 2.76 folds or
2.18 folds higher than that in the parental HepG2 or
SMMC7721 cells respectively (Additional file 1: Table S1).
The arsenic trioxide resistant cell lines, HepG2/As and
SMMC7721/As, were insensitive to Nutlin-3; and the IC50
was 1.9 and 1.77 fold higher than that in HepG2 and
SMMC7721 cells respectively (Additional file 1: Table S1).
Arsenic trioxide (2 μM) induced significant apoptosis in
HepG2 and SMMC7721 cells, but not in the SMMC7721/
As or HepG2/As cells (Figure 1C). Nutlin-3 could also in-
duce apoptosis in the parental HCC cells, but not in the
resistant cells (Figure 1C). As in our previous study [5],
the expression of MDM2, p-gp, and p53 were all increased
in arsenic resistant cells compared with that in the paren-
tal cells (Figure 1D).
Acquired mutation of p53 contributed to arsenic trioxide
resistance in HCC
Then, we analyzed the mutation status of p53 gene in
HepG2/As and SMMC7721/As cells. Results indicated
that the two cell lines exhibited different mutations
(Additional file 2: Table S2), which raised the question
about the exact role of mutp53 in arsenic trioxide resist-
ance. To address this question, we used siRNA to knock
down mutp53 in HepG2/As and SMMC7721/As cells be-
fore these cells were exposed to arsenic trioxide treatment.
Results indicated that siRNA significantly decreased the
level of mutp53 in HepG2/As and SMMC7721/As cells
(Figure 2A). The results of MTT assay suggested that
p53 knockdown significantly increased the sensitivity
of HepG2/As and SMMC7721/As cells to arsenic tri-
oxide (Figure 2B). Apoptosis assays showed that p53
knockdown significantly increased the percentage of apop-
totic cells after arsenic trioxide treatment (Figure 2C).
Western blot results suggested that downstream genes of
p73 (Noxa and puma) were increased after p53 knock-
down (Figure 2D). Previous studies have suggested that
mutp53 could upregulate multidrug resistance protein 1
(MDR1) gene expression [15]. Consistently, we found that
the expression of p-gp was notably decreased by p53
knockdown (Figure 2D). To further determine the signifi-
cance of mutp53 in arsenic trioxide resistance, we intro-
duced Lenti-mutp53 plasmid with V5 tag into HepG2,
SMMC7721 and Hep3B cells. The levels of exogenous
V5-tagged mutant p53 protein were determined using
Western blot after selection, as shown in Figure 2E. The
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mutp53 obviously decreased the sensitivity of HCC cells
to arsenic trioxide and resulted in arsenic trioxide resist-
ance compared with the vector control (Figure 2F). Taken
together, these results supported the hypothesis that p53
mutations were responsible for arsenic trioxide resistance
in HCC.
Mutp53 promotes migration and invasion in arsenic
trioxide resistant HCC cells
We have also compared the metastatic abilities between
the arsenic trioxide resistant cells and the parental cells.
Results of two chamber transwell assays indicated that
HepG2/As and SMMC7721/As cells had stronger abil-
ities of migration and invasion than the corresponding
parental cell lines (Figure 3A). Mutp53 has been illus-
trated to promote tumor metastasis in different cancers
[11,12]. Consistent with previous reports, our results
indicated that mutp53 knockdown dramatically de-
creased the migration and invasion abilities of arsenic
trioxide resistant cells, suggesting that mutp53 plays
an important role in the enhanced metastatic potential
(Figure 3B). Given that mutp53 promotes migration and
invasion in arsenic trioxide resistant HCC cells, we further
investigated the effect of mutp53 on epithelial-mesenchymal
transition (EMT), a critical event in tumor metastasis.
Western blot results showed higher expression of E-
cadherin, lower expression of N-cadherin and vimentin in
HepG2/As and SMMC7721/As cells transfected with p53
siRNA compared with cells transfected with control siRNA
(Additional file 3: Figure S1). Consistent with the results of
immunofluorescence, p53 knockdown markedly reduced
the levels of N-cadherin and vimentin in HepG2/As and
SMMC7721/As cells (Figure 3C).
Combination of arsenic trioxide and Nutlin-3 induces
more apoptosis and synergistically inhibits the metastasis
to lung
Previous studies proved that Nutlin-3 showed synergistic
effects when used in combination with other innovative
drugs, such as TRAIL or bortozemib [16]. To investigate
whether Nutlin-3 could cooperate with arsenic trioxide to
inhibit tumor growth, we treated HCC cells with Nutlin-3,
arsenic trioxide or both before MTT assays. The combin-
ation of Nutlin-3 (10 μM) and arsenic trioxide (2 μM)
showed increased proliferation inhibition of HCC cells,
approximate 41%-59% (Figure 4A). The apoptosis induc-
tion by Nutlin-3/arsenic trioxide combination was also
Figure 1 Influence of arsenic trioxide or Nutlin-3 on HCC cell viability and apoptosis. All HCC cell lines were treated with arsenic trioxide
or Nutlin-3 for 48 h and 72 h respectively. (A and B) The cell viability was determined using MTT assay. Data are presented as mean±SD, ***:
P<0.001. (C) The apoptosis was examined using Annexin V-FITC Apoptosis Detection Kit. ***: P< 0.001 compared with the control. (D) The
expression of MDM2, p53 and p-gp was investigated by Western blot in indicated cell lines.
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alone (Figure 4B). Western blots showed that although the
expression of MDM2 had no apparent changes in the ar-
senic trioxide treated and combined groups (Figure 4C),
the expression of E2F-1 and p73 was increased in HepG2/
As and SMMC7721/As cells treated with the combination.
The levels of p73 downstream genes, such as puma and
Noxa were upregulated, and the Bcl-2 family member
Bax, was also increased after arsenic trioxide treatment.
Nutlin-3 can enhance the effects of arsenic trioxide on the
above genes (Figure 4C). However, the decrease of mutp53
and p-gp could only be observed in the combined group.
Figure 2 Mutp53 plays an important role in HCC arsenic trioxide resistance. (A) Knockdown of mutp53 in HCC resistant cells. (B) MTT
assays were performed after cells were treated with arsenic trioxide for 48 h. ***: P<0.001 versus negative siRNA-transfected cells. (C) Cells were
treated with arsenic trioxide (2 μM) for 48 h before performing apoptosis assay. **, P<0.01 versus negative siRNA-transfected cells. Histograms
represent averages of three independent experiments. (D) Cells were treated with arsenic trioxide (2 μM) for 24 h after siRNA transfection (48 h).
The target proteins were detected by Western blot analyses. (E) One representative Western blot from three independent experiments demonstrates
the accumulation of the V5-tagged exogenous mutant p53 in each cell lines. (F) MTT assays were performed after cells were treated with arsenic
trioxide for 48 h. ***: P<0.001 versus vector control cell lines.
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ide to inhibit the migration and invasion of arsenic triox-
ide resistant HCC cells (Additional file 4: Figure S2).
Nutlin-3 could inhibit the function of p-gp and increase
the intracellular arsenicals in resistant cells
The fluorescent p-gp substrates, rhodamine 123 and JC-1,
were used to investigate the influence of Nutlin-3 on
p-gp-mediated substance efflux as described [14]. Results
indicated that rhodamine123 and JC-1 were pumped more
from two arsenic resistant cells comparing to the corre-
sponding parental cells (Figure 4D). We then examined
whether Nutlin-3 could inhibit the efflux of fluorescent
materials by p-gp. The results indicated that Nutlin-3 in-
duced intra-cellular accumulation of rhodamine123 and
JC-1 in HepG2/As and SMMC7721/As cells (Figure 4E).
Subsequently, the gross of arsenical in cells was compared
among HepG2, SMMC7721, HepG2/As and SMMC7721/
As cell lines by atomic fluorescence spectrometry (Figure 4F).
The intracellular arsenical in HepG2 was 0.0855 μg/10
6
cells after cultured in 2 μM arsenic trioxide medium
for 2 h, and was 2 fold higher than that in HepG2/As
(0.042 μg/10
6 cells). Similarly, the intracellular arsenical
in SMMC7721 (0.131 μg/10
6 cells) was 1.7 fold higher
than that in SMMC7721/As (0.077 μg/10
6 cells). However,
the intracellular arsenical of HepG2/As was increased and
reached 0.066 μg/10
6 cells, when arsenic trioxide was ap-
plied with 20 μM Nutlin-3 for 2 h. The intracellular arsen-
ical of SMMC7721/As was strongly accumulated and
reached 0.224 μg/10
6 cells after the treatment of both ar-
senic trioxide and Nutlin-3. It’s worth to note that 40 μM
verapamil (a p-gp inhibitor) induced accumulation of
Figure 3 Mutp53 contributed to the increased metastatic potential of HCC resistant cells. (A) The migration and invasive abilities of HCC
parental and arsenic trioxide resistant cells were determined by trans-well assays in chambers coated with matrigel (for invasion assays) or without
matrigel (for migration assays). Left panels: representative images; right panels: quantifications of average number of cells/field. *P<0. 05 ,** P<0. 01 ,
***P<0.001, two-way ANOVA with Bonferroni post-test. (B) Results of the migration and invasion assays for the HepG2/As and SMMC7721/As cells
transfected with p53 siRNA or control siRNA. (**P<0.01, ***P<0.001, two-way ANOVA with Bonferroni post-test). (C) Single and merged images were
taken to show immunofluorescence staining of N-cadherin (green) and vimentin (red) accompanied by the cell nucleus (blue) stained by DAPI.
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0.24 μg/10
6 cells respective) as same as 20 μM Nutlin-3,
which was coincident with our previous results [5].
Nutlin-3 disrupts the binding of p73 with MDM2 when in
combination with arsenic trioxide
As reported, p73 could bind to the MDM2 N-terminal
hydrophobic pocket, which is the region targeted by
Nutlin-3 [10]. Only the full length TAp73, but not
DNp73 isoforms that lack the TA domain, would be ex-
pected to bind MDM2. Utilizing a TA-specific antibody
raised against the N-terminus of p73, we performed co-
immunoprecipitation to evaluate and confirm the effects
of Nutlin-3 on the p73-MDM2 interaction in resistant
cells. We found that in untreated, arsenic trioxide treated
HCC resistant cells, p73 binds to MDM2. However,
Nutlin-3 treatment largely inhibited this binding in
the presence of arsenic trioxide (Figure 4G).
Nutlin-3/arsenic trioxide combination could synergistically
decrease mutant p53 in arsenic trioxide resistant HCC
cells
The slight decrease of mutp53 by arsenic trioxide afore-
mentioned in Figure 4C might provide a rationale for
the new mechanism of mutp53 degradation mediated by
Nutlin-3/arsenic trioxide combination. Recently, several
studies reported that arsenic could degrade mutp53
or ΔNp63 [17,18]. In the current study, we treated the
HepG2/As and SMMC7721/As cells with different doses
of arsenic trioxide for 10 h. Results indicated that single
use of arsenic trioxide could decrease mutp53 only if
the concentration was above 8 μM( A d d i t i o n a lf i l e5 :
Figure S3A), which was highly above the clinically rele-
vant dose. To investigate whether Nutlin-3 could decrease
the dose needed for mutp53 degradation by arsenic triox-
ide, resistant cells were treated with various doses of ar-
senic trioxide in the presence of Nutlin-3 (20 μM). The
results showed that mutp53 was considerably decreased
by arsenic trioxide at a dose as low as 2 μM (Additional
file 5: Figure S3B). It might be due to the inhibition of
p-gp by Nutlin-3, which enables more arsenic trioxide
to enter the HCC resistant cells to degrade mutp53.
Nutlin-3 potentiates the antitumor activity of arsenic
trioxide in an orthotopic hepatic tumor model and
cooperates with arsenic trioxide to inhibit the metastasis
to lung
Based on the in vitro results, we designed experiments
to determine the effects of Nutlin-3 and/or arsenic triox-
ide on orthotopically implanted hepatic tumors in nude
mice. Luciferase-transfected SMMC7721/As cells were
implanted in the liver of nude mice and the hepatic tu-
mors were assessed by the bioluminescence IVIS on days
7, 14, 21, and 28. The bioluminescence imaging results
(Figure 5A,B) indicated a gradual increase in tumor vol-
ume in the control group. Nutlin-3 or arsenic trioxide at
the current dose could not efficiently inhibit the hepatic
tumor growth. However, combination of Nutlin-3 and ar-
senic trioxide notably inhibited the tumor growth com-
pared with the other three groups. We then examined the
expression of the cell proliferation marker (Ki-67) and
apoptosis marker (cleaved caspase-3) in tumor tissues. The
results showed that combination of arsenic trioxide and
Nutlin-3 significantly downregulated the expression of
Ki-67 in tumor tissues compared with the groups treated
with arsenic trioxide or Nutlin-3 alone (Figure 5C,D). The
results also showed that only the combination could in-
duce significant apoptosis as suggested by the cleaved
caspase-3 staining (Figure 5C,D). In addition, the levels of
p53 and p-gp in the tumor tissues had also been assessed
using Western blot. As shown in Additional file 6: Figure
S4, the results were consistent with that in vitro, which
further strengthened the conclusions based on the in vitro
data. To examine the therapeutic efficacy of arsenic triox-
ide and Nutlin-3 against tumor metastasis, HepG2/As
cells were injected into nude mice via tail vein to imitate
tumor lung metastasis. We found that when arsenic
trioxide or Nutlin-3 was administrated alone, the average
number of foci per mouse was not significantly reduced.
However, the average number of foci was obviously
(See figure on previous page.)
Figure 4 The synergetic effects of arsenic trioxide and Nutlin-3 on HCC resistant cells. (A and B) The concentration of arsenic trioxide
applied here was 2 μM, and Nutlin-3 was 20 μM. Cell viability and apoptosis were determined after treatment for 48 h. **P<0.01, ***P<0.001,
versus cells treated with arsenic trioxide or Nutlin-3 alone. (C) Protein expression was compared among untreated, arsenic trioxide, Nutlin-3 and
Nutlin-3/arsenic trioxide groups in HepG2/As and SMMC7721/As cells. Cells had been cultured in the medium without any arsenic trioxide for at
least one week. The concentration of rhodamine 123 and JC-1 was 0.1 μM. (D) The fluorescence of rhodamine 123 and JC-1 in HepG2/As and
SMMC7721/As cells. Cells were incubated with rhodamine 123 and JC-1 for 60 min, and for another 60 min to efflux. **P<0.01,***P<0.001.
(E) The inhibition of efflux was depended on the concentration of Nutlin-3. Nutlin-3 at different concentration was added with rhodamin 123 or
JC-1 into medium and incubated for 60 min. Rho123, rhodamine 123. *P<0.05, **P<0.01, ***P<0.001, versus control cells. (F) Nutlin-3 and R(+)
verapamil assisted to increase the intracellular arsenic. All the cells were cultured with 2 μM arsenic trioxide, while treated groups were added
20 μM Nutlin-3 or 40 μM verapamil respectively and incubated for 2 h. *P< 0.05, **P<0.01, ***P< 0.001. (G) Nutlin-3 inhibits binding of p73 to
MDM2 when in combination with arsenic trioxide. Untreated cells, cells treated with 2μΜ arsenic trioxide, cells treated with 20 μM Nutlin-3, and
cells treated with arsenic trioxide/Nutlin-3 combination for 24 h were immune-precipitated with an anti-MDM2 antibody. Immunocomplexes were
subjected to immunoblotting with anti-MDM2 and anti-p73 antibodies.
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arsenic trioxide and Nutlin-3 could synergistically inhibit
the metastasis to lung.
Discussion
Anti-cancer drug resistance is always a big problem
obstructing the development of cancer chemotherapy.
Usually, resistant cancer cells might have more than two
bio-functions that help them to evade the lethal attack
of chemotherapy. This is why we have not received any
encouraging result from the use of competitive inhibitor
of drug efflux. In the current study, we reported that a
series of stepwise arsenic trioxide selections could in-
duce p53 mutations in HCC cells, which led to the
activation and stabilization of mutp53. The results fur-
ther suggested that mutp53 might take part in the ac-
quired arsenic resistance and the increased metastatic
abilities of resistant HCC cells. It has been reported pre-
viously that p73 could be induced by a wide variety of
chemotherapeutic drugs, including arsenic trioxide [9].
P73, which shares sequence homology with p53, is rarely
mutated in human cancer, but has been reported to be
inactivated by mutp53 or MDM2 [19,20]. We found the
same phenomenon that p73 could be induced by arsenic
trioxide in HCC cells here. To reactivate p73, two possible
ways, Nutlin-3 or mutp53 knockdown, alone or in com-
bination with arsenic trioxide were applied in the treat-
ment of resistant HCC cells. Nutlin-3, a small-molecule
Figure 5 Nutlin-3 potentiates the anti-tumor effects of arsenic trioxide in vivo. (A) Representative bioluminescence images corresponding
to the SMMC7721/As orthotopic hepatic tumors formed in the liver of the nude mice. (B) Volume of SMMC7721/As orthotopic tumors was
determined at different time points. Data points represent the mean±SD. (***P<0.001, two-way ANOVA with Bonferroni post-test). (C) Representative
images of sections stained with anti-Ki-67 antibody, or with anti-cleaved caspase-3 antibody. (D) Cells expressing Ki-67 were counted to calculate the
proliferation index; cleaved caspase-3-positive cells were counted to give the apoptosis index. (*P<0 .0 5 ,* *P<0.01, ***P<0.001, two-way ANOVA with
Bonferroni post-test). (E) The representative H&E staining of pulmonary metastasis (arrows) on 5wk (left panel) and the average number of foci per
mouse were calculated (right panel); (***P<0.001, two-way ANOVA with Bonferroni post-test).
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tor in many malignant tumors [16]. Our results indicated
that Nutlin-3 was effective in primitive HCC cells, while
arsenic resistant cells showed resistance to it. Interestingly,
either Nutlin-3 or p53 knockdown combined with arsenic
trioxide could induce significant growth inhibition and
apoptosis in arsenic trioxide sensitive and resistant HCC
cells. We further found that the synergistic effects were
due to the activation of p73 pathway and the competitive
inhibition of drug efflux.
Recently, several studies reported that Nutlin-3, used
alone or in combination with other chemotherapeutic
drugs, such as sorafenib or Dasatinib could promote the
synergistic cytotoxicity, irrespectively of p53 status [21,22].
Zauli et al. demonstrated that Nutlin-3 plus Dasatinib
showed significant synergistic antileukemic effects in both
p53 wild-type and p53 mutated B chronic lymphocytic
leukemias. These studies suggested that the combination
of Nutlin-3 and other innovative drugs might offer a novel
therapeutic strategy for tumors with p53 mutation, which
usually have a worse prognosis [22]. Moreover, Nutlin-3
was also found to be a substrate of p-gp and inhibit the
drug efflux of p-gp [14]. We proved that Nutlin-3 could
inhibit the efflux of rhodamine 123 and JC-1 by p-gp in a
concentration dependent manner. Furthermore, Nutlin-3
could also inhibited the efflux of arsenic and gathered
intracellular arsenic in HepG2/As and SMMC7721/As
cells. Nutlin-3 could not induce significant growth inhib-
ition in arsenic resistant cells, despite non-resistant cells
were sensitive to it. The over efflux of Nutlin-3 from
resistant cells by p-gp might be the reason of this in-
sensitivity. As same as arsenical, it is difficult to reach
the threshold of lethal dose for intracellular Nutlin-3
in arsenic resistant cells under a low concentration of
Nutlin-3. However, the combination of Nutlin-3 and
arsenic trioxide effectively overcome the drug resistance
through both competitive inhibition of drug efflux and
interference of p73-MDM2 interaction. Taken together,
these results suggested that the combination of Nutlin-3
and cytotoxic agent would be a promising way to treat
malignant cells, even resistant ones.
According to the results of the current study, targeting
either p-gp or negative p73 regulators could be a method
to solve drug resistance in p53 mutant HCC cells, but it is
not the most effective one. As resistant cancer cells have
multiple ways to evade cell death, we should find a man-
ner to block those ways simultaneously. In this study, be-
sides the finding that Nutlin-3 could inhibit the drug
efflux and the activity of MDM2, we found that arsenic
trioxide could also degrade mutp53, but only at a high
dose. Nutlin-3 could decrease the dose of arsenic trioxide
needed for mutp53 degradation, possibly through the
inhibition of p-gp. It is possible that solid tumor with
mutp53 may have the same mechanisms for drug resistance.
This suggests that Nutlin-3 could assist arsenic trioxide
or other anticancer drugs to treat malignant disease,
especially when drug resistance appears. The in vivo ex-
periments indicated that the administration of Nutlin-3
or arsenic trioxide alone could not inhibit the growth
or metastasis of arsenic trioxide resistant tumors in nude
mice models. However, when the two agents were used
in combination, the tumor growth and metastasis were
significantly inhibited and almost completely eliminated
in vivo.
Conclusions
Herein, the major findings of the present study are: a)
acquisition of p53 mutation contributed to the resistance
of HCC cells to arsenic trioxide; b) activation of p73 by
p53 knock down or Nutlin-3 could overcome arsenic tri-
oxide resistance; c) Nutlin-3/arsenic trioxide combin-
ation could inhibit the tumor growth and metastasis of
arsenic trioxide resistant HCC cells effectively through
mutp53 degradation and activating p73 both in vivo and
in vitro (Figure 6). In conclusion, this study suggests that
the combined treatment of arsenic trioxide plus Nutlin-3
might offer a novel therapeutic approach for HCC, espe-
cially arsenic trioxide resistant ones that have bad progno-
sis and urgently need innovative therapeutic strategies.
Materials and methods
Reagents
Arsenic trioxide (Sigma, USA) was stocked at 2 mM and
stored at 4°C. Nutlin-3 (Cayman, USA) was dissolved in
DMSO at 40 mM and stored at −20°C. R (+) Verapamil
(Sigma, USA) was stocked at 1 mM and stored at 4°C.
Rhodamin 123, JC-1 and DAPI were purchased from Beyotime
(Shanghai, China). RPMI1640, DMEM and fetal bovine
serum were also purchased from Invitrogen.
Cell culture
The p53 status of HepG2, HuH-7 and Hep3B cell lines
was confirmed in IARC TP53 Database (http://p53.iarc.
fr/CellLines.aspx) or reference [23]. HepG2/As and
SMMC7721/As cell lines were isolated from HepG2
and SMMC7721 cell lines, by a series of stepwise se-
lections via treatment with increasing concentrations
of arsenic trioxide as described previously [5]. HepG2,
HepG2/As, SMMC7721, and SMMC7721/As were
cultured in DMEM with 10% FBS. HepG2/As and
SMMC7721/As were maintained in medium contain-
ing 2 μM arsenic trioxide. HuH-7 cell line was pur-
chased from Xiangya central experiment laboratory
(Zhongnan University, China), and Hep3B cell line
was purchased from American Type Culture Collec-
tion (ATCC). The firefly luciferase gene plasmid-pGL3
vector (Promega, Madison, WI) was transfected into
Zheng et al. Molecular Cancer 2014, 13:133 Page 9 of 12
http://www.molecular-cancer.com/content/13/1/133SMMC7721/As cells to establish the SMMC7721/As-
Luci stable cell line after selection.
Cytotoxicity assay
Cytotoxicity assays were performed using MTT assay as
described previously [5,24].
Western blotting
Standard Western blot assays were performed as de-
scribed [5,24]. The following antibodies were used for
immunoblotting: anti-β-actin (C4), anti-p-gp (D-11), anti-
p53 (FL-393), anti-Bax, anti-p73 (H-79), anti-E2F-1 (KH95)
were all purchased from Santa Cruz Biotechnology.
The MDM2 antibody (2A10), N-cadherin, E-cadherin and
vimentin, PUMA and Noxa antibodies were all purchased
from Abcam.
Flow cytometry
To investigate ABC transporter–mediated substance efflux,
cells were incubated with rhodamine 123 (0.1 μmol/L) and
JC-1 (0.1 μmol/L) for 60 min. Then, cells were washed
with PBS and incubated for another 60 min before ana-
lyzed by flow cytometry (FACSCalibur, BD) as described
previously [14]. Similarly, to examine the function of
Nutlin-3, 5-20 μM Nutlin-3 was applied simultaneously
with rhodamine 123 and JC-1 for 60 min. Fluorescence
was analyzed after washing and 60 min incubation. To
analyze the apoptosis induced by arsenic trioxide or
Nutlin-3, Annexin V-FITC Apoptosis Detection Kit (BD
Biosciences) was used according to the protocol. The cell
cycle distribution was determined using the CycleTEST™
PLUS DNA Reagent Kit (BD Biosciences) according
to the protocol and analyzed by flow cytometry (Beckman
Coulter FC500).
SMMC7721/As orthotopic hepatic tumor experiments
SMMC7721/As-luciferase-transfected (Luci-SMMC7721/As)
cells were harvested from subconfluent cultures and washed
once in serum-free medium and resuspended in PBS.
Only suspensions consisting of single cells, with >90% via-
bility, were used for the injections. Luci-SMMC7721/As
cells (5×10
6) were implanted into the liver of the nude
mice as described [24]. After one week of implantation,
mice were randomized into the following treatment
groups (n=10/group) based on the bioluminescence mea-
sured after IVIS imaging: (a) Control (treated with vehi-
cles); (b) arsenic trioxide (i.p., 5 mg/kg/d); (c) Nutlin-3
(p.o., 200 mg/kg, twice a day); (d) arsenic trioxide (i.p.,
5 mg/kg/d)+Nutlin-3 (p.o., 200 mg/kg, twice a day). Mice
were imaged by the bioluminescence IVIS Imaging System
weekly and then mice were sacrificed.
In vivo metastasis analysis
HepG2/As cells (1× 10
6/0.2 ml) were injected into nude
mice by way of tail vein to imitate tumor metastasis.
Experimental animals were randomized into the follow-
ing treatment groups (n =10/group): (a) Control (treated
with vehicles); (b) arsenic trioxide (i.p., 5 mg/kg/d); (c)
Nutlin-3 (p.o., 200 mg/kg, twice a day); (d) arsenic triox-
ide (i.p., 5 mg/kg/d) +Nutlin-3 (p.o., 200 mg/kg, twice a
day). The mice were killed 5 weeks after the inoculation
and lungs were removed and fixed in formaldehyde. The
lung metastases were confirmed by H&E staining.
Figure 6 A schematic presentation for the possible mechanisms of arsenic trioxide resistance in HCC and the synergistical anticancer
mechanisms of arsenic trioxide/Nutlin-3 combination in the current study.
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Statistical analyses were performed with the GraphPad
Prism software package (v. 4.02; GraphPad Prism Soft-
ware Inc, San Diego, CA) or SPSS 16.0 software (SPSS,
Chicago, IL, USA). Values were expressed as mean ±SD
values using the Student’s t-test and one-way ANOVA
with the Bonferroni’s correction when comparing more
than two groups. P <0.05 was considered to be statisti-
cally significant.
Detailed description of other Materials, Methods and
the primers used for p53 mutation detection can be found
in the Additional file 7 and Additional file 8: Table S3.
Additional files
Additional file 1: Table S1. IC50 of arsenic trioxide or Nutlin-3 in different
HCC cell lines. IC50 was examined using MTT assay. HCC cells were treated
with arsenic trioxide for 48 h or Nutlin-3 for 72 h. Values are means±SD of
at least three independent experiments performed in triplicate.
Additional file 2: Table S2. p53 mutations in arsenic trioxide resistant
HCC cell lines.
Additional file 3: Figure S1. The levels of E-cadherin, N-cadherin and
Vimentin in the SMMC7721/As and HepG2/As cells without treatment or
cells transfected with p53 siRNA or control siRNA was examined by
western blotting assays.
Additional file 4: Figure S2. The results of migration and invasion
assays in HepG2/As or SMMC7721/As cells after arsenic trioxide, Nutlin-3
or arsenic trioxide/Nutlin-3 treatment for 24 h. (*P< 0.05, ***P <0.001,
two-way ANOVA with Bonferroni post-test).
Additional file 5: Figure S3. Nutlin-3 cooperates with arsenic trioxide
to degrade mutp53 protein in HCC arsenic trioxide resistant cells. (A)
Western blots were prepared with extracts from HCC resistant cells
untreated or treated with different concentrations of arsenic trioxide for
10 h, and then probed with antibodies against p53 and actin. (B) Western
blots were prepared with extracts from HCC resistant cells untreated or
treated with arsenic trioxide of different concentrations in the presence of
Nutlin-3 for 10 h, and then probed with antibodies against p53 and actin.
Additional file 6: Figure S4. The expression of p53 and p-gp in the
orthotopic hepatic tumor tissues from the indicated group was examined
by western blot. Actin was used as internal control.
Additional file 7: Supplemental materials, methods and figure
legends.
Additional file 8: Table S3. The sequences of the primers used for p53
mutation analysis.
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